

Shionogi has been Selected as one of the "Excellent Integrated Reports" by the GPIF's Domestic Equity Managers

OSAKA, Japan, March 5, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") has announced the "SHIONOGI INTEGRATED REPORT 2020" has been selected as the "Excellent Integrated Reports" selected by the domestic equities managers of the Government Pension Investment Fund (GPIF) - the world's largest retirement scheme.

GPIF asked domestic equities managers to select up to 10 companies each for an "Outstanding Integrated Reports" and a "highly improved integrated report". In this selection, a total of 77 companies were selected as "Excellent Integrated Reports", and among them, Shionogi was listed as a company that received high evaluations from multiple investment institutions.

Shionogi aims to continuously keep having balanced dialogues with our all stakeholders such as our shareholders/investors, our customers, our surrounding society and our employees with a view to combining our sustainable growth with our society's sustainable growth. We continuously strive to improve our high-level disclosure including integrated report even more in order to further improve our corporate value.

For Further Information, Contact:

Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release



Reference:

- **The SHIONOGI INTEGRATED REPORT 2020**
<https://www.shionogi.com/global/en/investors/ir-library/annual-report-integrated-report.html>
- **Press release on February 24 2021 by GPIF**
https://www.gpif.go.jp/investment/20210224_integration_report.pdf